Skip to main content
Premium Trial:

Request an Annual Quote

Idec Inks Deal to Use ExonHit s HTP Sequencing Technique for Identifying Antigen Targets

NEW YORK, Jan. 7—Idec Pharmaceuticals and ExonHit Therapeutics said Monday that they would collaborate to develop new antigen targets for antibody therapy.

 

In the partnership, Idec will use ExonHit's Datas technique, a method for identifying disease-relevant mRNA sequence changes by analyzing alternative RNA splicing. The ExonHit technique allows these changes to be identified without high-throughput sequencing.

 

The partnership will identify targets for prostate cancer.

 

In the deal, Idec gets worldwide exclusive rights to antibody-based therapeutic applications of new targets. ExonHit, in return, will receive an upfront payment, milestones, and royalty payments on products that may emerge from the collaboration.

 

Further financial details were not revealed.

 

ExonHit, which was founded in 1997, is based in Paris with a subsidiary in Gaithersburg, Md. The company raised €30 million ($26.8 million) in its third round of private financing in December. It is currently developing treatments for Lou Gehrig's disease and other central nervous system diseases.

 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.